Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02352844 · ClinicalTrials.gov registry record · Phase 2
Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutations
A Phase 2 study of Solid Tumor and Solid Malignancy, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT02352844: Completed Phase 2 study of Solid Tumor and Solid Malignancy, sponsored by Washington University School of Medicine.
NCT02352844 is a Phase 2 study of Solid Tumor and Solid Malignancy that has completed, run by Washington University School of Medicine. The registered enrollment target is 12 participants, below the 222-participant average among 196 other Solid Tumor trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02352844, a Phase 2 study of Solid Tumor and Solid Malignancy, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to look at participants with solid tumor malignancies and specific mutations respond to treatment with everolimus.
Primary Outcome
The primary endpoint will be to describe the response rate using RECIST 1.1. Response rate will be defined as complete response (disappearance of all target lesion) plus partial response (a least a 30% decrease in the sum of diameters of target lesions).
Conditions Studied
Interventions
- DRUG Everolimus
Study Locations (1)
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2015-10-07 |
| Est. Completion | 2017-08-15 |
| Phase | Phase 2 |
What the finished NCT02352844 record still lists
NCT02352844 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 222-participant average among 196 other Solid Tumor trials with a reported enrollment target (95% lower).
The record links to 2 conditions, with Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which Everolimus is the first listed.
NCT02352844 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT02352844 about?
NCT02352844 is a clinical study titled "Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutations". The purpose of this research study is to look at participants with solid tumor malignancies and specific mutations respond to treatment with everolimus.
What is the current status of trial NCT02352844?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2015-10-07. Estimated completion is 2017-08-15.
What conditions does trial NCT02352844 study?
This clinical trial studies the following conditions: Solid Tumor, Solid Malignancy.
What interventions are being tested in trial NCT02352844?
The interventions under investigation include: Everolimus (DRUG).
Who is sponsoring clinical trial NCT02352844?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02352844 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02352844's enrollment target sits among peer trials
12 190th of 196 higher than 4 of 196 other Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors
RECRUITING · Phase 2
-
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
RECRUITING · Phase 2
-
A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients
RECRUITING · Phase 2
-
A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors
RECRUITING · Phase 2
-
A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib
RECRUITING · Phase 2
-
Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI